Abciximab
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
| Trivial name | Abciximab |
| Catalog Number | TP-100CL |
| Alternative Name(s) | Abciximab |
| Research Area | Haemostasis and thrombosis |
| Molecular Formula | C6462H9964N1690O2049S48 |
| CAS# | 143653-53-6 |
| Purity | >90% |
| Size | 1 mg |
| Supplier Page | https://www.creativebiolabs.net/Abciximab-22438.htm |
| Additional Information | Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting. |